Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-10-19
Based on 402 first isolates · MED-B · Cystitis (lower UTI) · 2024-10-20 → 2025-10-19
Internal medicine B
Per-organism detail: MED-B urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 84 % (80 %–87 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (7 %), Klebsiella pneumoniae (4 %), Pseudomonas aeruginosa (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
86 %
88 %
n = 24
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
84 %
92 %
n = 24
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
81 %
75 %
n = 24
ciprofloxacin CIP
trend · Escherichia coli
80 %
79 %
n = 24
ceftriaxone CRO
trend · Escherichia coli
79 %
83 %
n = 24
mecillinam MEC
trend · Escherichia coli lower UTI only
79 %
79 %
n = 24
75 %
83 %
n = 24
trimethoprim TMP
trend · Escherichia coli lower UTI only
72 %
75 %
n = 24
48 %
46 %
n = 24
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
12 %
13 %
n = 24
3 %
0 %
n = 24
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
2 %
0 %
n = 24

Most likely organisms for this profile

Escherichia coli
58 %
Klebsiella pneumoniae
11 %
Enterococcus faecalis
9 %
Proteus mirabilis
7 %
Citrobacter freundii
4 %
Pseudomonas aeruginosa
3 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.